Scarica l'app Stockscreener
0.4987
4.83%
-0.0253
Dopo l'orario di chiusura:
.51
0.0113
+2.27%
Rallybio Corp Borsa (RLYB) Ultime notizie
Should I buy Rallybio Corporation stock before earningsFastest-growing stock picks - jammulinksnews.com
Rallybio’s RLYB116 Study: A Potential Game-Changer in Complement Inhibition - TipRanks
Rallybio Corporation Stock Analysis and ForecastMassive profits - jammulinksnews.com
Is Rallybio Corporation a good long term investmentSky-high profits - jammulinksnews.com
What analysts say about Rallybio Corporation stockHigh-octane gains - jammulinksnews.com
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN
What drives Rallybio Corporation stock priceUnmatched market gains - PrintWeekIndia
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug - MSN
10 Best Small Cap AI Stocks to Buy According to Analysts - Insider Monkey
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - MSN
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
What makes Rallybio Corporation stock price move sharplyFree Best Performing Stock Alerts - Newser
Why Rallybio Corporation stock attracts strong analyst attentionFree Join Group - Newser
How Rallybio Corporation stock performs during market volatilityCarefully Curated High Return Stocks - Newser
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - MSN
Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN
We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate - simplywall.st
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Insider Monkey
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Yahoo Finance
Rallybio sells REV102 programme to Recursion for up to $25m - Pharmaceutical Business review -
Rallybio Drops 9.98% Despite Q1 Progress, Recursion Deal - AInvest
Rallybio sells HPP treatment program to Recursion for up to $25 million By Investing.com - Investing.com South Africa
Rallybio sells HPP treatment program to Recursion for up to $25 million - Investing.com Nigeria
Biotech Stocks Climb With Recursion's Bold Move Forward - Finimize
Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio - Investing.com India
Recursion Pharmaceuticals Rises With Rallybio Acquisition Move - Finimize
Recursion, Rallybio Shares Rise After Deal on Joint Hypophosphatasia Candidate - MarketScreener
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - citybiz
RallyBio - Hartford Business Journal
Rallybio sells interest in drug program in deal worth up to $25M - Hartford Business Journal
Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement - TipRanks
Rallybio shifts gears, cashing out of Recursion pact to extend runway - Fierce Biotech
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):